Stem Cell Therapy for Type 1 Diabetes by Jayashree on June 9, 2021 at 9:45 PM
Recently developing a promising approach for treating this condition is reported in the journal
Nature Communications by Scientists at the Salk Institute using stem cells to create insulin-producing cells (called beta cells) to replace non-functional pancreatic cells with proven results in mouse model. Stem cells are an extremely promising approach for developing many cell therapies, including better treatments for type 1 diabetes, says Salk Professor Juan Carlos Izpisua Belmonte, the paper s senior author.
‘New stem cell therapy can effective to treat type 1 diabetes.’
The investigators started with human pluripotent stem cells (hPSCs) having the potential to become any kind of cell found in the adult body coaxed into beta cells in a stepwise fashion that mimicked pancreatic development using various growth factors and chemicals resulted in about 10 to 40 percent of cel
BOSTON After working on cutting edge technology, Dr Khalid Shah and his team finally succeeded in getting a slot in this year’s 12 technologies that will impact brain tumour management in future.
Calgary, Alberta (Newsfile Corp. - May 31, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE:2VF0) ("Hemostemix" or the "Company") reminds shareholders that due to COVID-19, its Annual and
(0)
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Calgary, Alberta (Newsfile Corp. - May 29, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ( Hemostemix or the Company ) is pleased to announce that it has obtained preliminary approval from the TSX Venture Exchange to close a $2,500,000 convertible debenture order from a director for Debenture Units priced at $0.40 per Unit as detailed below. On May 28, 2021, Hemostemix filed its Financial Statements and Management Discussion and Analysis for the period ending March 31, 2020 on SEDAR. This financing segregates the litigation risk from the equity risk and enables the Company to move forward with its business plans, stated Thomas Smeenk, CEO.